NEW YORK, October 13, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK), Medtronic, Inc. (NYSE: MDT), Covidien plc (NYSE: COV) and Amgen Inc. (NASDAQ: AMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7112-100free.
--
Johnson & Johnson Research Reports
On October 6, 2014, Johnson & Johnson's vision care solutions provider arm Johnson & Johnson Vision Care Companies (JJVCC) announced that its Sight for Kids program, which it runs in partnership with Lions Club International Foundation, has now reached 20 million children with free, volunteer-directed vision screenings. JJVCC is now expanding the program into Greater Nairobi, Kenya and Ankara, Turkey, the first two countries to receive its services in Africa and Europe. "As our worldwide footprint grows, we know that the Sight for Kids model works and has made a significant impact on children in underserved communities," said Robert Hollin, Worldwide President, Johnson & Johnson Medical Limited. As per the Company, Sight for Kids, one of the longest running and largest public-private vision-screening programs in the world, has grown by nearly 1.8 million children screened per year since its launch in 2002. The full research reports on Johnson & Johnson are available to download free of charge at:
http://www.analystsreview.com/Oct-13-2014/JNJ/report.pdf
--
Merck & Co. Inc. Research Reports
On October 8, 2014, Merck & Co. Inc. (Merck) announced that it will present a new data from clinical studies of the Company's investigational, oral, once-daily, fixed-dose combination chronic hepatitis C treatment grazoprevir/elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, also known as The Liver Meeting®. Merck informed that the meeting is scheduled to take place at the John B. Hynes Veterans Memorial Convention Center in Boston, Massachusetts, from November 7 - November 11, 2014. "Tremendous progress has been made in recent years in the understanding of chronic hepatitis C and its treatment, but it is important that we continue to advance the development of therapies to treat diverse populations of HCV-infected patients," said Dr. Eliav Barr, Vice President, Infectious Diseases, Merck Research Laboratories. "Merck's broad and systematic hepatitis C clinical development program is designed with this goal in mind, and is generating important insights into the potential of grazoprevir/elbasvir across multiple viral genotypes and patient populations." The full research reports on Merck are available to download free of charge at:
http://www.analystsreview.com/Oct-13-2014/MRK/report.pdf
--
Medtronic, Inc. Research Reports
On October 3, 2014, Medtronic, Inc. (Medtronic) unveiled a new financing plan to complete the acquisition of Covidien plc (Covidien). The Company said that it now plans to use approximately $16 billion in external financing to fund the transaction, rather than using cash from its foreign subsidiaries, as previously planned. According to a report by Wall Street Journal, the move has come in the backdrop of recent changes in the U.S. tax-rules that would make it tougher for companies like Medtronic to use their overseas cash without paying U.S. taxes. Medtronic said that the transaction is still expected to be accretive to its cash earnings in FY 2016 and thereafter, despite the additional expense of the new financing. Moreover, the Company also stated that its FY 2015 revenue outlook and EPS guidance remain unaffected by this external financing transaction. Medtronic expects the transaction to close in late 2014 or early 2015. The full research reports on Medtronic are available to download free of charge at:
http://www.analystsreview.com/Oct-13-2014/MDT/report.pdf
--
Covidien plc Research Reports
On October 7, 2014, Covidien plc (Covidien) announced in a regulatory disclosure that its issued share capital, excluding treasury shares, consisted of 452,488,239 ordinary shares as of the close of business on October 6, 2014. Further, as of the same day, Covidien confirmed that it had outstanding 1.63 million restricted share units, 13.08 million options to purchase ordinary shares, and performance share units that entitle holders to receive up to a maximum of 1.46 million ordinary shares upon vesting. The full research reports on Covidien are available to download free of charge at:
http://www.analystsreview.com/Oct-13-2014/COV/report.pdf
--
Amgen Inc. Research Reports
On October 8, 2014, Amgen Inc. (Amgen) announced that its Phase 3 study evaluating safety and efficacy of its biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe plaque psoriasis met the primary endpoint. Amgen informed that the primary endpoint was the Psoriasis Area and Severity Index (PASI) percent improvement from baseline to week 16 of treatment. "Results from Amgen's biosimilar Phase 3 plaque psoriasis study met the primary endpoint for efficacy and showed comparable safety and immunogenicity to adalimumab, which further demonstrates the Company's commitment to provide patients with access to high-quality medicines," said Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen. Amgen also informed that it has six biosimilar molecules in development and it expects to launch the portfolio starting in 2017. On the same day, shares of the Company gained 2.97% to close at $140.07. The full research reports on Amgen are available to download free of charge at:
http://www.analystsreview.com/Oct-13-2014/AMGN/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
